Axa
CRSP icon

Axa’s CRISPR Therapeutics CRSP Stock Holding History

Axa’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,359
Closed -$229K – 1076
2024
Q1 		$229K Sell
3,359
-2,399
-42% -$172K ﹤0.01% 1013
2023
Q4 		$360K Buy
+5,758
New +$318K ﹤0.01% 973
2022
Q4 		– Sell
-112,559
Closed -$7.36M – 1154
2022
Q3 		$7.36M Buy
112,559
+9,639
+9% +$699K 0.03% 496
2022
Q2 		$6.25M Buy
102,920
+8,910
+9% +$524K 0.02% 528
2022
Q1 		$5.9M Buy
94,010
+21,101
+29% +$1.32M 0.02% 604
2021
Q4 		$5.53M Buy
72,909
+872
+1% +$76.2K 0.01% 642
2021
Q3 		$8.06M Buy
72,037
+11,861
+20% +$1.49M 0.02% 553
2021
Q2 		$9.74M Buy
60,176
+53,176
+760% +$6.47M 0.03% 517
2021
Q1 		$853K Buy
+7,000
New +$1.06M ﹤0.01% 999
2018
Q4 		– Sell
-5,100
Closed -$226K – 1312
2018
Q3 		$226K Hold
5,100
– – ﹤0.01% 1278
2018
Q2 		$300K Buy
+5,100
New +$291K ﹤0.01% 1230

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Axa's CRSP Position: Q2 2024 in Review

Axa sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 3,359 shares — an estimated $229K sold.

Axa first reported a position in CRSP in Q2 2018 and held it in 11 quarters. The position peaked at $9.74M in Q2 2021. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Axa reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Axa sold 3,359 CRISPR Therapeutics shares in Q2 2024, an estimated $229K.
  • Axa first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 11 quarters.
  • Axa's CRISPR Therapeutics position peaked at $9.74M in Q2 2021.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Axa's 13F filing for Q2 2024, filed 14 Aug 2024.